Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia-Reference-Cited by-同舟云学术

Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia

Published:2010-09-29 Issue:5 Volume:151 Page:430-434
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Advani Anjali S.,Gundacker Holly M.,Sala-Torra Olga,Radich Jerald P.,Lai Raymond,Slovak Marilyn L.,Lancet Jeffrey E.,Coutre Steve E.,Stuart Robert K.,Mims Martha P.,Stiff Patrick J.,Appelbaum Frederick R.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08387.x/fullpdf

Reference15 articles.

1. An interphase fluorescence in situ hybridization (FISH) assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies;Bobadilla;British Journal of Haematology,2007

2. Immunohistochemical variation of human nucleoside transporters in primary breast cancer;Dabbagh;Biochemical and Biophysical Research Communications,2001

3. Results of a Phase I-II study of clofarabine in combination with cytarabine (ara-c) in relapsed and refractory leukaemias;Faderl;Blood,2005

4. Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (ALL); an MRC UKALL12/ECOG 2993 study;Fielding;Blood,2007

5. Clofarabine, a novel nucleoside analog, is active in paediatric patients with advanced leukaemia;Jeha;Blood,2004

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of ALL in adults: 2024 ELN recommendations from a European expert panel;Blood;2024-05-09

2. Treatment of Adult B- and T-Cell Acute Lymphoblastic Leukemia: An Overview of Current Treatments and Novel Advances;Clinical Management of Acute Lymphoblastic Leukemia;2022

3. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial;Blood Advances;2021-12-09

4. Targeting CD22 for the Treatment of B-Cell Malignancies;ImmunoTargets and Therapy;2021-07

5. CCN2 (Cellular Communication Network factor 2) in the bone marrow microenvironment, normal and malignant hematopoiesis;Journal of Cell Communication and Signaling;2021-01-11